Status and perspectives in chemotherapy of Hodgkin's disease.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002051:Burkitt Lymphoma / Q000188:drug therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008466:Mechlorethamine / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D008938:Mitosis / Q000187:drug effects; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D011344:Procarbazine / Q000008:administration & dosage / Q000627:therapeutic use; D012075:Remission, Spontaneous; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001565:Benzoates; D003561:Cytarabine; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone